Available online at www.sciencedirect.com
SCIENCE DIRECT®
Bioorganic & Medicinal Chemistry Letters
Bioorganic & Medicinal Chemistry Letters 14 (2004) 2373–2374

Erratum

Erratum to "α-Substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents" [Bioorg. Med. Chem. Lett. 13 (2003) 4223]☆

R. Jain,[a] A. Sundram,[a] S. Lopez,[a] G. Neckermann,[b] C. Wu,[a] C. Hackbarth,[a] D. Chen,[a] W. Wang,[a] N. S. Ryder,[b] B. Weidmann,[b] D. Patel,[a] J. Trias,[a] R. White[a] and Z. Yuan[a,*]

[a]*Vicuron Pharmaceuticals (formerly Versicor Inc), 34790 Ardentech Court, Fremont, CA 94555, USA*
[b]*Novartis Institutes for Biomedical Research, Inc, 100 Technology Square, Cambridge, MA 02139, USA*

The Publisher regrets that Table 2 was incorrectly reproduced. The corrected version is shown below.

Table 2. Summary of in vitro activities of succinic hydroxamate analogues (see Fig. 1 for general structure)



Compd	α-	P_2'	P_3'	SPN(3)	SAU(3)	HIN(3)	PDF	MMP-7	K562
V-a	H	L-pro.	**a**	16	4–8	0.25–0.5	0.010	>200	84
V-b	H	L-pro.	**b**	0.13–0.5	0.06–0.25	0.5–1	0.009	34	7
V-c	H	L-pro.	**c**	0.13–0.5	0.06–0.13	0.5–2	0.012	35	3
V-d	H	L-pro.	**d**	0.06–0.13	0.06	0.5–2	0.003	11	2
V-e	H	L-pro.	**e**	0.06–0.25	0.06–0.25	1–4	0.009	4	2
V-f	H	L-pro.	**f**	0.06–0.25	0.25–1	0.5–2	0.029	13	1
V-g	H	L-pro.	**g**	0.06–0.25	0.06–0.25	0.5–2	0.021	5	0.09
V-h	H	L-pro.	**h**	1–2	2–16	4–8	0.017	45	100
E	*S*-OH	L-pro.	**i**	8	0.25–1	4–16	0.001	28	>28
J	*R*-OH	L-pro.	**i**	8–16	0.5–4	2–4	0.006	128	NT
F	*R*-OMe	L-pro.	**i**	64	32–>64	32–>64	0.05	NT	6
G	*S*-OSO_3H	L-pro.	**i**	16–32	1–4	16–32	0.030	>200	112
N	*S*-F	L-pro.	**i**	2–4	0.25–1	1–2	0.002	111	>28
M	*R*-F	L-pro.	**i**	16–32	2–8	16–32	0.016	139	NT
R	*S*-OH	L-aze.	**j**	1–4	0.5–4	4–8	0.0067	>200	14
S	*S*-OH	L-pro.	**j**	4–16	1–4	2–8	0.008	105	44
T	*S*-OH	L-thiaz.	**j**	>64	16–>64	>64	0.277	>200	83
U	*S*-OH	L-pip.	**j**	16	8–>64	16–32	0.0067	196	13

(*continued on next page*)

☆ DOI of original article 10.1016/j.bmcl.2003.07.020
* Corresponding author. Tel.: +1-510-739-3026; fax: +1-510-739-3086; e-mail: zyuan@vicuron.com

0960-894X/$ - see front matter © 2003 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2004.02.029

Table 2. (*continued*)

Compd	α-	P_2'	P_3'	SPN(3)	SAU(3)	HIN(3)	PDF	MMP-7	K562
X-a	*S*-F	L-pro.	**a**	2–4	2–4	0.5–1	0.001	133	>200
Y-a	*R*-F	L-pro.	**a**	32–64	4–16	4–8	0.027	>32	>200
X-j	*S*-F	L-pro.	**j**	0.25–1	0.5–2	0.5–1	0.013	35.3	>200
X-k	*S*-F	L-pro.	**k**	0.25–0.5	0.5–1	1–2	0.016	23.9	102.9
X-l	*S*-F	L-pro.	**l**	0.25–0.5	0.12–0.5	2	0.013	13.1	21.4
X-m	*S*-F	L-pro.	**m**	0.25–2	0.5–1	0.12–0.5	0.0013	38.1	>200
Y-m	*R*-F	L-pro.	**m**	4–8	2–8	4–8	0.016	186.7	97.5
X-n	*S*-F	L-pro.	**n**	2–16	4–16	4–8	0.007	61.3	>200
X-o	*S*-F	L-pro.	**o**	0.13–0.5	0.5–1	2–4	0.009	16.2	64.9
X-c	*S*-F	L-pro.	**c**	0.13–0.25	0.13–0.5	1–2	0.002	0.9	24.1
Y-c	*R*-F	L-pro.	**c**	1–2	0.25–1	8–32	0.002	5.8	33.7
X-p	*S*-F	L-pro.	**p**	0.06–0.13	0.13–0.5	2–4	0.001	0.1	6.7
X-f	*S*-F	L-pro.	**f**	0.06–0.13	0.13–0.5	1–4	0.001	0.3	4.2
X-q	*S*-F	L-pro.	**q**	1	0.5–2	1–2	0.029	>200	>200
X-r	*S*-F	L-pro.	**r**	1–2	0.25–1	0.25–1	0.020	>200	>200
X-s	*S*-F	L-pro.	**s**	0.5–2	0.25–2	1–4	0.022	>200	>200
X-t	*S*-F	L-pro.	**t**	0.25–2	1–8	2–4	0.013	>200	>200
X-u	*S*-F	L-pro.	**u**	0.06–0.13	0.25–0.5	4–16	0.006	23.6	66.5
X-v	*S*-F	L-pro.	**v**	0.06–0.25	0.25–1	16	0.006	26.7	122.2
W-a	*S*-OH	L-pro.	**a**	16–32	2–4	2	0.010	63.5	>200
W-j	*S*-OH	L-pro.	**j**	1–4	4–16	2–8	0.008	43.7	105
W-l	*S*-OH	L-pro.	**l**	1–4	0.5–2	4–8	0.008	20.5	21.6
W-w	*S*-OH	L-pro.	**w**	4–16	4–16	4–16	0.007	>29	180.8
W-x	*S*-OH	L-pro.	**x**	4–16	1–4	8–16	0.008	>27	177.9
W-o	*S*-OH	L-pro.	**o**	1–2	1–4	8–32	0.003	15.4	49.6
W-q	*S*-OH	L-pro.	**q**	4–16	1–4	2–8	0.017	>200	>200
W-r	*S*-OH	L-pro.	**r**	8–16	2–4	1–4	0.024	>200	>200
W-s	*S*-OH	L-pro.	**s**	4–32	1–4	16–32	0.013	108.4	>200
W-t	*S*-OH	L-pro.	**t**	8	8	4	0.004	183.3	80.9
W-u	*S*-OH	L-pro.	**u**	0.25–1	0.06–0.25	32–64	0.005	9.7	109.7
W-v	*S*-OH	L-pro.	**v**	1–4	0.25–4	64	0.003	17.1	>200

MIC values are expressed in μg/mL for SPN (*S. pneumoniae*), SAU (*S. aureus*), and HIN (*H. influenzae*). Enzyme inhibition and cytotoxicity are expressed as IC_{50} (μM) for PDF (*E. coli* Ni-containing peptide deformylase), MMP-7 (matrix metallo protease-7), and K562 (human leukemia cell K562 (ATCC #CCL-243)).